Patients with overweight or obesity who used maridebart cafraglutide experienced significant weight loss at 1 year, according ...

Designed to transform the treatment landscape for diabetes, metabolic syndrome and weight loss, Laxxon's breakthrough oral GLP-1 agonist, LXM.2, offers a once-daily robust alternative to injections ...

Eli Lilly slashes the revenue guidance for the fourth quarter and fiscal 2024 but offers a bullish outlook for 2025.

The race is on for new drugs that suppress appetite, improve glucose regulation and can replace injections. But do they ...

Dr Daniel Rosen, who is a surgeon and obesity medicine specialist based out of New York, says a 'legitimate number' of his ...

Weight loss jabs such as Wegovy are “lifelong treatments” and most people who stop taking them will lose the effects, a ...

Ozempic is available in India but may not be as widely accessible as in other countries. Keep reading as we answer some FAQs ...

Semaglutide combined with automated insulin delivery enhances glucose control in type 1 diabetes, lowering insulin ...

BioSpace recaps 2024’s top venture capital rounds in biopharma, from Xaira Therapeutics’ blockbuster $1B raise to ...

Eli Lilly’s CEO Dave Ricks cited stocking levels and unexpected market dynamics in Q4 2024 in the GLP-1RA market.

A study by Mass General Brigham investigators shows persistent racial disparities and growing sex disparities between ...